Outcome | Initial Screening | In person Screening | Baseline Assessment | 12-week intervention | Immediate Post 12-week Assessment | 3-months follow-up Interview | 6-months follow-up Assessment |
---|---|---|---|---|---|---|---|
Cognitive | |||||||
 BICAMS* | |||||||
SDMT | Â | X | Â | Â | X | Â | X |
  Token Test |  | X |  |  |  |  |  |
 BICAMS* | |||||||
  CVLT |  |  | X |  | X |  | X |
 BICAMS* | |||||||
  BVMT-R |  |  | X |  | X |  | X |
  WTAR or NART |  |  | X |  |  |  |  |
Physical | |||||||
 Visual Acuity test |  | X |  |  |  |  |  |
 ActiGraph Device |  | X |  | X** |  |  |  |
 CMI |  |  | X |  | X |  | X |
 6MWT |  |  | X |  | X |  | X |
 IET |  |  | X |  | X |  | X |
 Functional MRI*** |  |  | X |  | X |  | X |
PRO´s | |||||||
 Fitness Questionnaire**** | X |  |  |  |  |  |  |
 GLTEQ | X |  |  |  |  |  |  |
 Demographic form |  | X |  |  |  |  |  |
 BDI-II |  | X |  |  |  |  |  |
 FAMS |  |  | X |  | X |  | X |
 EQ-5D-5L |  |  | X |  | X |  | X |
 MSIS-29-V2 |  |  | X |  | X |  | X |
 MSWS-12 |  |  | X |  | X |  | X |
 PDQ-20 |  |  | X |  | X |  | X |
 MFIS |  |  | X |  | X |  | X |
 HADS |  |  | X |  | X |  | X |
Customized | |||||||
 Phone Interview | X |  |  |  |  |  |  |
 Consent form |  | X |  |  |  |  |  |
 Medication list |  | X |  |  | X |  | X |
 Goal Setting Sheet |  |  |  | X |  |  |  |
 Adverse Event form***** |  |  |  | X |  |  |  |
 Post Intervention Interview |  |  |  |  |  | X |  |
 Post Intervention Survey |  |  |  |  |  |  | X |
 Serious Adverse Event form***** |  |  |  |  |  |  | X |